NEU 0.00% $19.97 neuren pharmaceuticals limited

Ann: Prader-Willi syndrome IND for NNZ-2591 approved by FDA, page-5

  1. 5,867 Posts.
    lightbulb Created with Sketch. 17381
    Neuren previously reported positive results in the Magel-2 mouse model of Prader-Willi syndrome, in which treatment with NNZ-2591 for 6 weeks normalized fat mass, insulin levels, IGF1 levels and all behavioural deficits.

    And this is why I expect this particular trial to be keenly watched...
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.